GlassScriptPhysician profile
Amber N Shepard
NPI 1104309129
$10,678.09
in general payments reported to CMS, 2019-2025
56 companies · $2,782 in 2025
The $2,782 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $854 · 2022: $1,781 · 2023: $2,781 · 2024: $2,480 · 2025: $2,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,042.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $745.03 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $742.69 | 2021-2025 | Opdivo, Pomalyst, Krazati |
| Celgene Corporation | $686.19 | 2021-2025 | Pomalyst, Reblozyl, Breyanzi |
| Incyte Corporation | $685.87 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $676.41 | 2021-2025 | Calquence, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $565.63 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $462.16 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Janssen Biotech, INC. | $434.59 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Genentech USA, INC. | $408.76 | 2021-2025 | Perjeta, Phesgo, Tecentriq |
| Pfizer INC. | $339.68 | 2023-2025 | |
| Lilly USA, LLC | $317.43 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $301.34 | 2021-2025 | |
| Genzyme Corporation | $294.87 | 2021-2025 | |
| Daiichi Sankyo INC. | $283.96 | 2023-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $282.75 | 2021-2025 | Libtayo, Lynozyfic |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $270.95 | 2021-2025 | Ninlaro, Alunbrig, Iclusig |
| Gilead Sciences, INC. | $256.42 | 2023-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $234.93 | 2023-2025 | Fotivda |
| Amgen INC. | $224.69 | 2021-2023 | Vectibix, Nplate, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $224.12 | 2021-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Glaxosmithkline, LLC. | $193.55 | 2021-2025 | Jemperli, Ojjaara, Blenrep |
| Eisai INC. | $165.37 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $155.84 | 2022-2024 | Precisetumor |
| Beigene USA, INC. | $124.57 | 2021-2025 | Tevimbra, Brukinsa |
| Astellas Pharma US INC | $100.27 | 2023-2024 | Padcev, Xtandi, Xospata |
| Kite Pharma, INC. | $89.76 | 2025 | |
| Emd Serono, INC. | $89.28 | 2023-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $81.19 | 2021-2022 | |
| Geron Corporation | $80.24 | 2024-2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $78.85 | 2022-2023 | Imbruvica |
| Exelixis INC. | $65.08 | 2024 | Cabometyx |
| Sanofi-Aventis U.S. LLC | $64.49 | 2021-2022 | |
| Morphosys, US INC. | $58.44 | 2022 | |
| Stemline Therapeutics INC. | $54.14 | 2022-2023 | Orserdu |
| Mirati Therapeutics, INC. | $51.92 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $49.06 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.85 | 2021-2024 | Gilotrif |
| Pharmacosmos Therapeutics INC. | $46.66 | 2021-2025 | Monoferric |
| Adc Therapeutics America, INC. | $46.41 | 2025 | |
| Genmab U.S., INC. | $41.64 | 2023-2024 | Epkinly |
| Beone Medicines USA, INC. | $38.28 | 2025 | Tevimbra, Brukinsa |
| Deciphera Pharmaceuticals INC. | $36.41 | 2021 | |
| Caris Mpi, INC. | $32.91 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $32.58 | 2022-2023 | Lorbrena, Xalkori, Mektovi |
| Epizyme, INC. | $29.83 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $28.02 | 2022 | |
| Azurity Pharmaceuticals, INC. | $21.08 | 2025 | Vivimusta, Danziten |
| Apellis Pharmaceuticals, INC. | $20.37 | 2022 | |
| Clovis Oncology, INC. | $19.00 | 2022 | |
| Sobi, INC | $17.64 | 2023 | |
| Pharmaessentia USA Corporation | $17.44 | 2024 | Besremi |
| Blueprint Medicines Corporation | $15.96 | 2021 | |
| Novocure INC. | $15.07 | 2025 | Optune Lua (Novottf-200t) |
| Myovant Sciences INC. | $15.04 | 2021 | |
| Acceleron Pharma, INC. | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.